Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Analysis of MBL2 geno- and phenotypes in SSc cases and controls

From: Potential role of the lectin pathway of complement in the pathogenesis and disease manifestations of systemic sclerosis: a case-control and cohort study

Variables Cases Controls Univariate matched analysis
(n = 90) (n = 90) OR (95% CI) Pvalue
MBL2 exon variants, n (%)     
  A/A 56 (62) 59 (66) Reference  
  A/O 30 (33) 25 (28) 1.2 (0.7-2.3) 0.5
  O/O 4 (4) 6 (7) 0.6 (0.1-3.1) 0.5
MBL2 promoter variant, n (%)     
  Y/Y 46 (51) 47 (52) Reference  
  Y/X 36 (40) 38 (42) 1.0 (0.6-1.7) 1
  X/X 8 (9) 5 (6) 1.7 (0.5-6.2 0.4
MBL2 genotypes, n (%)     
  High producing 48 (53) 54 (60) Reference  
  Intermediate producing 24 (27) 18 (20) 1.5 (0.7-3.0) 0.3
  Low producing 18 (20) 18 (20) 1.1 (0.5-2.5) 0.8
MBL levels (μg/ml), median (IQR) 1.1 1.0 1.3 (1.0-1.7)a 0.06
MBL <0.5 μg/ml, n (%) 62 (69) 65 (72) 1.2 (0.6-2.5) 0.6
  1. MBL2 genotypes were classified as low- (XA/YO, YO/YO), intermediate- (XA/XA, YA/YO) or high- (YA/YA, XA/YA) producing genotypes with exon variant alleles collectively designated as O and the wild-type gene as A, and the promoter variant allele and the wild-type gene designated as X and Y, respectively. aPer 1 μg/ml increase in MBL serum levels. CI, confidence interval; IQR, interquartile range; MBL, mannose-binding lectin; OR, odds ratio; SSc, systemic sclerosis.